JP2014500960A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500960A5 JP2014500960A5 JP2013538809A JP2013538809A JP2014500960A5 JP 2014500960 A5 JP2014500960 A5 JP 2014500960A5 JP 2013538809 A JP2013538809 A JP 2013538809A JP 2013538809 A JP2013538809 A JP 2013538809A JP 2014500960 A5 JP2014500960 A5 JP 2014500960A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- subject
- bin1
- level
- skeletal muscle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000970561 Homo sapiens Myc box-dependent-interacting protein 1 Proteins 0.000 claims description 72
- 102100021970 Myc box-dependent-interacting protein 1 Human genes 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 51
- 210000002027 skeletal muscle Anatomy 0.000 claims description 42
- 102000001708 Protein Isoforms Human genes 0.000 claims description 25
- 108010029485 Protein Isoforms Proteins 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 16
- 230000003247 decreasing effect Effects 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- 206010003694 Atrophy Diseases 0.000 claims description 6
- 230000037444 atrophy Effects 0.000 claims description 6
- 208000001076 sarcopenia Diseases 0.000 claims description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 3
- 230000004968 inflammatory condition Effects 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 230000001272 neurogenic effect Effects 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41168310P | 2010-11-09 | 2010-11-09 | |
| US61/411,683 | 2010-11-09 | ||
| PCT/US2011/059574 WO2012087437A2 (en) | 2010-11-09 | 2011-11-07 | Bin1 expression as a marker of skeletal muscle mass and neurological conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500960A JP2014500960A (ja) | 2014-01-16 |
| JP2014500960A5 true JP2014500960A5 (enExample) | 2014-12-25 |
| JP5866126B2 JP5866126B2 (ja) | 2016-02-17 |
Family
ID=46314702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013538809A Active JP5866126B2 (ja) | 2010-11-09 | 2011-11-07 | 骨格筋量および神経性状態のマーカーとしてのｂｉｎ１発現 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9891232B2 (enExample) |
| EP (1) | EP2638403B1 (enExample) |
| JP (1) | JP5866126B2 (enExample) |
| AU (2) | AU2011345312A1 (enExample) |
| CA (1) | CA2817519C (enExample) |
| WO (1) | WO2012087437A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120094300A1 (en) | 2009-04-24 | 2012-04-19 | Robin Shaw | Bin1 as a Prognostic Marker in Cardiovascular Disease |
| WO2012054764A1 (en) | 2010-10-20 | 2012-04-26 | The Regents Of The University Of California | Body fluid bin1 as a marker of cardiac health |
| WO2013049666A1 (en) | 2011-09-30 | 2013-04-04 | Sarcotein Diagnostics, Llc | Bin1 expression as a marker of cancer |
| JP6742330B2 (ja) | 2015-03-02 | 2020-08-19 | サーコーティン ダイアグノスティックス エルエルシー | 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現 |
| JP6539511B2 (ja) * | 2015-06-17 | 2019-07-03 | 花王株式会社 | 運動機能の判定用マーカー |
| JP6886241B2 (ja) * | 2016-01-07 | 2021-06-16 | 味の素株式会社 | 骨格筋面積の評価方法 |
| CN109219615B (zh) * | 2016-05-02 | 2022-12-09 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CN118955712A (zh) | 2018-07-25 | 2024-11-15 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| US12173057B2 (en) | 2018-10-09 | 2024-12-24 | Ibex Biosciences, Inc. | Antibodies and therapeutic uses thereof |
| WO2022132859A1 (en) * | 2020-12-15 | 2022-06-23 | Arizona Board Of Regents On Behalf Of Arizona State University | Antibodies specific for qsox1 and methods of using the same |
| CN112794900B (zh) * | 2020-12-31 | 2022-10-25 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
| CN112778414B (zh) * | 2020-12-31 | 2022-04-15 | 中南大学湘雅二医院 | cBIN1抗体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6048702A (en) * | 1995-05-05 | 2000-04-11 | The Wistar Institute Of Anatomy And Biology | Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor |
| WO2001004354A2 (en) | 1999-07-07 | 2001-01-18 | Regeneron Pharmaceuticals, Inc. | Use of ras inhibitors of inhibiting muscle atrophy |
| US6831063B1 (en) * | 1999-08-31 | 2004-12-14 | The Wistar Institute Of Anatomy And Biology | Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor |
| US20090088482A1 (en) * | 2003-10-14 | 2009-04-02 | The Trustees Of Columbia University In The City New York | Compositions and Methods For Treating Heart Failure |
| WO2005113798A2 (en) | 2004-04-15 | 2005-12-01 | University Of Florida Research Foundation, Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
| WO2006009629A2 (en) * | 2004-06-10 | 2006-01-26 | New York University | Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same |
| WO2008008846A2 (en) * | 2006-07-11 | 2008-01-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Differential expression of molecules associated with intra-cerebral hemorrhage |
| US20120094300A1 (en) * | 2009-04-24 | 2012-04-19 | Robin Shaw | Bin1 as a Prognostic Marker in Cardiovascular Disease |
| WO2012054764A1 (en) * | 2010-10-20 | 2012-04-26 | The Regents Of The University Of California | Body fluid bin1 as a marker of cardiac health |
-
2011
- 2011-11-07 EP EP11850406.7A patent/EP2638403B1/en active Active
- 2011-11-07 AU AU2011345312A patent/AU2011345312A1/en not_active Abandoned
- 2011-11-07 JP JP2013538809A patent/JP5866126B2/ja active Active
- 2011-11-07 US US13/884,454 patent/US9891232B2/en active Active
- 2011-11-07 WO PCT/US2011/059574 patent/WO2012087437A2/en not_active Ceased
- 2011-11-07 CA CA2817519A patent/CA2817519C/en active Active
-
2017
- 2017-03-10 AU AU2017201661A patent/AU2017201661B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500960A5 (enExample) | ||
| JP2013060443A5 (enExample) | ||
| Angata et al. | Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation | |
| JP2023002583A (ja) | Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測 | |
| CN102816763B (zh) | 特异性结合于疟原虫乳酸脱氢酶pLDH的DNA适体 | |
| JP2013500941A5 (enExample) | ||
| JP2012115275A5 (enExample) | ||
| JP2010115195A5 (enExample) | ||
| EA201490384A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| JP2012012402A5 (enExample) | ||
| EA201290629A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| JP2012526530A5 (enExample) | ||
| WO2009116861A3 (en) | Diagnostic of pre-symptomatic metabolic syndrome | |
| JP2010536043A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2016029056A5 (enExample) | ||
| WO2007117444A3 (en) | Protein detection by aptamers | |
| NZ600828A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| JP2014502848A5 (enExample) | ||
| JP2016136963A5 (enExample) | ||
| JP2013531655A5 (enExample) | ||
| EA201291314A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| WO2008136848A4 (en) | Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease | |
| JP2013539369A5 (enExample) | ||
| JP2017502253A5 (enExample) |